ARTICLE | Financial News

Cue spikes after pricing $66.2M IPO

January 2, 2018 7:24 PM UTC

Cancer and autoimmune company Cue Biopharma Inc. (NASDAQ:CUE) climbed $4.13 (55%) to $11.63 in its first day of trading Tuesday after raising $66.2 million through the sale of 8.8 million shares at $7.50 in an IPO underwritten by MDB Capital Group and Feltl.

Spun out of the Albert Einstein College of Medicine in 2015, Cue has IP covering platforms to generate biologics that aim to activate or inhibit select T cell populations to treat cancer and autoimmune disease while avoiding the toxicities associated with chimeric antigen receptor (CAR) T cell therapies (see BioCentury, Jan. 27, 2017)...